Paper30899360
Therapeutic targeting of immune checkpoints with small molecule inhibitors.
Smith WM and 9 others. Am J Transl Res, 2019. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Therapeutic targeting of immune checkpoints with small molecule inhibitors. Papers, record 30899360. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30899360
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References99
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10365964 | Structure and ligand of a histone acetyltransferase bromodomain. | Nature | 1999 | https://conductscience.org/library/papers/10365964 | PubMed |
| 2 | 10485649 | Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. | Immunity | 1999 | https://conductscience.org/library/papers/10485649 | PubMed |
| 3 | 10601994 | Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses. | Eur J Immunol | 1999 | https://conductscience.org/library/papers/10601994 | PubMed |
| 4 | 10880530 | Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. | J Exp Med | 2000 | https://conductscience.org/library/papers/10880530 | PubMed |
| 5 | 11419179 | The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma. | Cancer Immunol Immunother | 2001 | https://conductscience.org/library/papers/11419179 | PubMed |
| 6 | 11584304 | The renaissance of GSK3. | Nat Rev Mol Cell Biol | 2001 | https://conductscience.org/library/papers/11584304 | PubMed |
| 7 | 11741888 | Small molecule ligands define a binding site on the immune regulatory protein B7.1. | J Biol Chem | 2002 | https://conductscience.org/library/papers/11741888 | PubMed |
| 8 | 12091876 | Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. | Nat Med | 2002 | https://conductscience.org/library/papers/12091876 | PubMed |
| 9 | 12646627 | Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. | J Immunol | 2003 | https://conductscience.org/library/papers/12646627 | PubMed |
| 10 | 12788368 | Structure-activity studies of a series of dipyrazolo[3,4-b:3',4'-d]pyridin-3-ones binding to the immune regulatory protein B7.1. | Bioorg Med Chem | 2003 | https://conductscience.org/library/papers/12788368 | PubMed |
| 11 | 1396582 | Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. | EMBO J | 1992 | https://conductscience.org/library/papers/1396582 | PubMed |
| 12 | 15485628 | Role of LAG-3 in regulatory T cells. | Immunity | 2004 | https://conductscience.org/library/papers/15485628 | PubMed |
| 13 | 15610849 | High-affinity small molecule inhibitors of T cell costimulation: compounds for immunotherapy. | Chem Biol | 2004 | https://conductscience.org/library/papers/15610849 | PubMed |
| 14 | 15971272 | Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. | Eur J Immunol | 2005 | https://conductscience.org/library/papers/15971272 | PubMed |
| 15 | 16307490 | Histone deacetylase inhibitors: discovery and development as anticancer agents. | Expert Opin Investig Drugs | 2005 | https://conductscience.org/library/papers/16307490 | PubMed |
| 16 | 16924108 | OX40 ligand shuts down IL-10-producing regulatory T cells. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/16924108 | PubMed |
| 17 | 16931720 | Reversal of the TCR stop signal by CTLA-4. | Science | 2006 | https://conductscience.org/library/papers/16931720 | PubMed |
| 18 | 17560335 | Genes that distinguish physiological and pathological angiogenesis. | Cancer Cell | 2007 | https://conductscience.org/library/papers/17560335 | PubMed |
| 19 | 17575071 | OX40 costimulation turns off Foxp3+ Tregs. | Blood | 2007 | https://conductscience.org/library/papers/17575071 | PubMed |
| 20 | 17785860 | A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. | J Immunol | 2007 | https://conductscience.org/library/papers/17785860 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41294857 | Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives. | Cells | 2025 | https://conductscience.org/library/papers/41294857 | PubMed |
| 40624659 | One step further in targeting acute leukemia by combining antibody-based immunotherapies and small molecule inhibitors. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/40624659 | PubMed |
| 39161771 | Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance. | Front Immunol | 2024 | https://conductscience.org/library/papers/39161771 | PubMed |
| 39026528 | Spatial proteomic profiling of tumor and stromal compartments in non-small-cell lung cancer identifies signatures associated with overall survival. | Clin Transl Immunology | 2024 | https://conductscience.org/library/papers/39026528 | PubMed |
| 38956700 | Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer. | Eur J Med Res | 2024 | https://conductscience.org/library/papers/38956700 | PubMed |
| 38833067 | A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors. | Invest New Drugs | 2024 | https://conductscience.org/library/papers/38833067 | PubMed |
| 38321096 | Investigation of the potential effects of estrogen receptor modulators on immune checkpoint molecules. | Sci Rep | 2024 | https://conductscience.org/library/papers/38321096 | PubMed |
| 38248769 | Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches. | J Pers Med | 2024 | https://conductscience.org/library/papers/38248769 | PubMed |
| 37999131 | Advances in Immunotherapy for Hepatocellular Carcinoma (HCC). | Curr Oncol | 2023 | https://conductscience.org/library/papers/37999131 | PubMed |
| 36982802 | Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36982802 | PubMed |
| 36551637 | Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36551637 | PubMed |
| 36413426 | Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy. | Mol Pharm | 2022 | https://conductscience.org/library/papers/36413426 | PubMed |
| 35757459 | Dual Effect of the Extract from the Fungus Coriolus versicolor on Lipopolysaccharide-Induced Cytokine Production in RAW 264.7 Macrophages Depending on the Lipopolysaccharide Concentration. | J Inflamm Res | 2022 | https://conductscience.org/library/papers/35757459 | PubMed |
| 34996924 | In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction. | Sci Rep | 2022 | https://conductscience.org/library/papers/34996924 | PubMed |
| 34858943 | Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts. | Front Chem | 2021 | https://conductscience.org/library/papers/34858943 | PubMed |
| 34452059 | Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy-Current Status and Future Perspectives. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/34452059 | PubMed |
| 33777676 | Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. | Acta Pharm Sin B | 2021 | https://conductscience.org/library/papers/33777676 | PubMed |
| 32988398 | Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1. | Genome Med | 2020 | https://conductscience.org/library/papers/32988398 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30899360
GET https://conductscience.org/api/papers/v1/30899360/references?page=2